Edition:
United Kingdom

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

240.89USD
4:23pm GMT
Change (% chg)

$-2.51 (-1.03%)
Prev Close
$243.40
Open
$241.90
Day's High
$242.43
Day's Low
$239.61
Volume
91,256
Avg. Vol
251,638
52-wk High
$265.87
52-wk Low
$209.93

Latest Key Developments (Source: Significant Developments)

Becton, Dickinson And Co Sets Quarterly Dividend Of $0.77 Per Share
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Becton Dickinson and Co ::SETS QUARTERLY DIVIDEND OF $0.77PER SHARE.SAYS DIVIDEND REPRESENTS INCREASE OF 2.7 PERCENT FROM PREVIOUS QUARTER.  Full Article

Becton Dickinson Announces Clinical Trial Data For The Lutonix 014 DCB
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Becton Dickinson and Co ::BD ANNOUNCES CLINICAL TRIAL DATA FOR THE LUTONIX® 014 DRUG-COATED BALLOON BELOW-THE-KNEE IDE TRIAL.BECTON DICKINSON - STUDY'S PRIMARY SAFETY ENDPOINT WAS MET SHOWING STATISTICALLY SIGNIFICANT SAFETY EQUIVALENCE BETWEEN LUTONIX 014 DCB & STANDARD PTA CATHETER.  Full Article

Becton Dickinson Says Entered 364-Day Term Loan Agreement
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Becton Dickinson and Co ::BECTON DICKINSON AND CO SAYS ON SEPTEMBER 6, CO ENTERED 364-DAY TERM LOAN AGREEMENT - SEC FILING.BECTON DICKINSON AND CO - TERM LOAN AGREEMENT IS A SENIOR UNSECURED TERM LOAN FACILITY THAT PROVIDED CO WITH $750 MILLION OF TERM LOANS.BECTON DICKINSON AND CO - BORROWINGS UNDER TERM LOAN FACILITY WERE USED TO PARTIALLY REFINANCE 3 YEAR TERM LOAN AGREEMENT, DATED AS OF MAY 12, 2017.  Full Article

BD Statement On Divestiture Of Advanced Bioprocessing Business
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Becton Dickinson and Co ::BD STATEMENT ON DIVESTITURE OF ADVANCED BIOPROCESSING BUSINESS.BECTON DICKINSON AND CO - EXPECTS TO RECORD A TAX GAIN ON TRANSACTION AT TIME OF CLOSING.BECTON DICKINSON - FOR FISCAL 2018, BD ESTIMATES CONTRIBUTION FROM ADVANCED BIOPROCESSING BUSINESS TO EPS OF ABOUT $0.13 TO $0.15 ON A FY BASIS.  Full Article

Thermo Fisher Scientific To Acquire Advanced Bioprocessing Business From BD
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Thermo Fisher Scientific Inc ::THERMO FISHER SCIENTIFIC TO ACQUIRE ADVANCED BIOPROCESSING BUSINESS FROM BD.THERMO FISHER SCIENTIFIC INC - BD'S ADVANCED BIOPROCESSING BUSINESS WILL BE INTEGRATED INTO THERMO FISHER'S LIFE SCIENCES SOLUTIONS SEGMENT.  Full Article

Becton Dickinson and Co Posts Q3 Adj Earnings $2.91/Shr
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Becton Dickinson and Co ::BD ANNOUNCES RESULTS FOR 2018 THIRD FISCAL QUARTER; RAISES FISCAL 2018 REVENUE GUIDANCE.Q3 EARNINGS PER SHARE $2.03.Q3 REVENUE $4.278 BILLION VERSUS I/B/E/S VIEW $4.24 BILLION.Q3 EARNINGS PER SHARE VIEW $2.86 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $10.95 TO $11.05.Q3 ADJUSTED EARNINGS PER SHARE $2.91.RAISING FULL FISCAL YEAR 2018 REVENUE GUIDANCE, EXPECTS GROWTH TO EXCEED 31.5 PERCENT ON A REPORTED BASIS.BECTON DICKINSON - FOR FY18, ON A COMPARABLE, CURRENCY-NEUTRAL BASIS, CO IS ALSO RAISING ITS REVENUE GUIDANCE, NOW EXPECTS GROWTH TO EXCEED 5.5 PERCENT.REAFFIRMS ACQUISITION OF C.R. BARD EXPECTED TO BE ACCRETIVE TO ADJUSTED. EARNINGS PER SHARE ON A HIGH-SINGLE DIGIT BASIS IN FISCAL 2019.  Full Article

Becton Dickinson Files For Potential Mixed Shelf Offering
Thursday, 26 Apr 2018 

April 26 (Reuters) - Becton Dickinson and Co ::BECTON DICKINSON AND CO FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING.  Full Article

Becton Dickinson Launches Circulating Cell-Free DNA Blood Collection Tube in Western Europe
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Becton Dickinson And Co ::BD LAUNCHES CIRCULATING CELL-FREE DNA BLOOD COLLECTION TUBE FOR CANCER AND NON-INVASIVE PRENATAL TESTING APPLICATIONS.BECTON DICKINSON AND CO - ‍COMMERCIAL AVAILABILITY OF CE-IVD MARKED PAXGENE BLOOD CCFDNA TUBE WITHIN EUROPEAN ECONOMIC AREA AND SWITZERLAND​.  Full Article

BD Statement On FDA Warning Letter For Preanalytical Systems Business Unit
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Becton Dickinson And Co ::BD STATEMENT ON FDA WARNING LETTER FOR PREANALYTICAL SYSTEMS BUSINESS UNIT.BECTON DICKINSON - AFTER FDA INSPECTION IN JULY, TOOK ACTION THAT CO BELIEVED FULLY ADDRESSED AGENCY'S INSPECTIONAL OBSERVATIONS.BECTON DICKINSON - "CAREFULLY REVIEWING" FDA'S FEEDBACK OUTLINED IN LETTER WITH HIGHEST SENSE OF URGENCY, TO PROVIDE FULL RESPONSE ON OR BEFORE FEB 1.  Full Article

FDA Issues Warning Letter To Becton Dickinson & Co
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - U.S. Food and Drug Administration::FDA WARNS BECTON DICKINSON & COMPANY OF SIGNIFICANT VIOLATIONS OF THE LAW AS PART OF ONGOING INVESTIGATION INTO LEAD TESTING ISSUES‍​.U.S. FDA SAYS BECTON DICKINSON'S VIOLATIONS INCLUDE MARKETING MODIFIED VERSIONS OF CERTAIN BD VACUTAINER BLOOD COLLECTION TUBES WITHOUT REQUIRED APPROVAL.FDA SAYS INSPECTION SHOWED BD VIOLATED LAW BY MAKING SIGNIFICANT CHANGE TO SOME OF ITS DEVICES WITHOUT NOTIFYING FDA.‍FDA​ SAYS VIOLATIONS WERE DISCOVERED THROUGH AN INSPECTION OF BECTON DICKINSON ’S NEW JERSEY FACILITY.FDA SAYS BECTON DICKINSON HAS UNTIL FEB 1, 2018 TO NOTIFY FDA ABOUT SPECIFIC STEPS CO HAS TAKEN TO ADDRESS FDA IDENTIFIED VIOLATIONS.FDA - BD DID NOT ADDRESS COMPLAINT OF VARIABILITY IN RESULTS WHEN SOME BD VACUTAINER BLOOD COLLECTION TUBES WERE USED WITH MAGELLAN DIAGNOSTICS’ LEADCARE TEST SYSTEMS.  Full Article

REFILE-COLUMN-U.S. court cases aim to rein in age-discrimination hiring practices

(Corrects paragraph 9 spelling to McCann instead of McGann) By Mark Miller CHICAGO, Sept 5 Dale Kleber is an experienced attorney, but when he spotted an ad back in 2014 for a corporate law position at a medical device and services company that specified “no more than seven years of experience,” he applied anyway. At age 58, Kleber had extensive experience working for law firms, as an in-house general counsel and in general management jobs. But he had been out of work si